338 related articles for article (PubMed ID: 10385663)
1. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases].
Seehofer D; Rayes N; Bechstein WO; Naumann U; Neuhaus R; Berg T; Hopf U; Langrehr JM; Steinmüller T; Platz KP; Müller AR; Neuhaus P
Z Gastroenterol; 2000 Sep; 38(9):773-83. PubMed ID: 11072673
[TBL] [Abstract][Full Text] [Related]
3. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
de Man RA; Bartholomeusz AI; Niesters HG; Zondervan PE; Locarnini SA
J Hepatol; 1998 Oct; 29(4):669-75. PubMed ID: 9824278
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
[TBL] [Abstract][Full Text] [Related]
5. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.
Gutfreund KS; Williams M; George R; Bain VG; Ma MM; Yoshida EM; Villeneuve JP; Fischer KP; Tyrrel DL
J Hepatol; 2000 Sep; 33(3):469-75. PubMed ID: 11020004
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.
Rosenau J; Bahr MJ; Tillmann HL; Trautwein C; Klempnauer J; Manns MP; Böker KHW
J Hepatol; 2001 Jun; 34(6):895-902. PubMed ID: 11451174
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.
Bartholomew MM; Jansen RW; Jeffers LJ; Reddy KR; Johnson LC; Bunzendahl H; Condreay LD; Tzakis AG; Schiff ER; Brown NA
Lancet; 1997 Jan; 349(9044):20-2. PubMed ID: 8988118
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
[TBL] [Abstract][Full Text] [Related]
10. [Dynamic changes of hepatitis B virus during treatment with lamivudine versus lamivudine plus famciclovir].
Hou J; Fen X; Nie Z
Zhonghua Gan Zang Bing Za Zhi; 2000 Apr; 8(2):81-3. PubMed ID: 10861109
[TBL] [Abstract][Full Text] [Related]
11. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
[TBL] [Abstract][Full Text] [Related]
12. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
[TBL] [Abstract][Full Text] [Related]
14. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
[TBL] [Abstract][Full Text] [Related]
15. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy.
Kim KH; Lee KH; Chang HY; Ahn SH; Tong S; Yoon YJ; Seong BL; Kim SI; Han KH
J Med Virol; 2003 Nov; 71(3):367-75. PubMed ID: 12966541
[TBL] [Abstract][Full Text] [Related]
16. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
Günther S; von Breunig F; Santantonio T; Jung MC; Gaeta GB; Fischer L; Sterneck M; Will H
J Hepatol; 1999 May; 30(5):749-54. PubMed ID: 10365797
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B: progress in the last 15 years.
Villamil FG
Liver Transpl; 2002 Oct; 8(10 Suppl 1):S59-66. PubMed ID: 12362301
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
Yang Y; Zhang Q; Cai CJ; Lu MQ; Li X; Jiang N; Jiang H; Xu C; Li H; Wang GS; Yi SH; Zhang J; Zhang JF; Yi HM; Zhang YC; Chen GH
Chin Med J (Engl); 2007 Aug; 120(16):1400-3. PubMed ID: 17825167
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
